Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalycilic Acid Resistance

Basit Öğe Kaydı
dc.authoridISIK, SERHAT/0000-0002-3477-5889|, Mustafa Cetin/0000-0001-7542-6602;
dc.contributor.authorCakmak, Muzaffer
dc.contributor.authorDemircelik, Bora
dc.contributor.authorCetin, Mustafa
dc.contributor.authorCetin, Zehra
dc.contributor.authorIsik, Serhat
dc.contributor.authorCicekcioglu, Hulya
dc.contributor.authorUlusoy, Feridun Vasfi
dc.date.accessioned2025-10-24T18:10:13Z
dc.date.available2025-10-24T18:10:13Z
dc.date.issued2016
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground: Acetylsalicylic acid (ASA) resistance in patients with coronary artery disease is an important medical problem that can affect treatment decision-making and outcomes. Cilostazol has been investigated to determine its effectiveness in patients with acetylsalicylic acid resistance. The aim of this study was to evaluate the antiplatelet efficacy of sequential administration of CLZ in patients with ASA resistance. Methods: A total of 180 patients were enrolled in our study. Patients with stable coronary artery disease were first given orally ASA 100 for 10 days, followed by collagen/epinephrine induced closure time (CTCEPI) measurements. Those who were found to be resistant to orally 100 mg of ASA were given orally 300 mg of ASA for an additional 10 days after which we repeated CTCEPI measurements. Those patients with resistance to orally 300 mg ASA were then given CLZ at a daily dose of orally 200 mg for 10 days followed by a final CTCEPI measurement. Results: The rate of resistance to 100 mg ASA was 81/180 (45%) compared to a rate of 35/81 (43.2%) with 300 mg ASA. Of the 35 patients found to be resistant to 300 mg ASA, 22 (62.9%) also failed to respond to CLZ treatment. Overall, sequential administration of 300 mg ASA and 200 mg CLZ resulted in a reduction in the number of non-responders from 45% to 12.2%. Conclusions: Initiation of CLZ could be of benefit in some patients with ASA-resistance for whom an effective anti-aggregant effect is of clinical importance.
dc.identifier.doi10.6515/ACS20150727A
dc.identifier.endpage327
dc.identifier.issn1011-6842
dc.identifier.issue3
dc.identifier.pmid27274173
dc.identifier.scopus2-s2.0-84969753212
dc.identifier.scopusqualityQ3
dc.identifier.startpage321
dc.identifier.urihttps://doi.org/10.6515/ACS20150727A
dc.identifier.urihttps://hdl.handle.net/20.500.12899/4053
dc.identifier.volume32
dc.identifier.wosWOS:000376219500009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaiwan Soc Cardiology
dc.relation.ispartofActa Cardiologica Sinica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectAngina pectoris; Cardiovascular outcome; Pharmacodynamics
dc.titleAntiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalycilic Acid Resistance
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu